Towards a pan-European consensus on the treatment of patients with colorectal liver metastases.

[1]  T. Seufferlein,et al.  Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  S. Curley,et al.  Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  D. Sargent,et al.  Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Y. Hasegawa,et al.  Pharmacogenetics of irinotecan: A promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecan , 2005, Investigational New Drugs.

[5]  J. Pignon,et al.  Hepatic and Extrahepatic Colorectal Metastases: When Resectable, Their Localization Does Not Matter, But Their Total Number Has a Prognostic Effect , 2005, Annals of Surgical Oncology.

[6]  C. Köhne,et al.  Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  L. Schwartz,et al.  Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Agnès Laplanche,et al.  Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  C. Bokemeyer,et al.  Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  C. Nadal,et al.  FAS/FAS Ligand Ratio: A Marker of Oxaliplatin-Based Intrinsic and Acquired Resistance in Advanced Colorectal Cancer , 2005, Clinical Cancer Research.

[11]  P. Schlag,et al.  Feasibility and risks of pre-operative chemotherapy (CT) with Folfox 4 and surgery for resectable colorectal cancer liver metastases (LM). Interim results of the EORTC Intergroup randomized phase III study 40983 , 2005 .

[12]  F. Lévi,et al.  Three-drug chronotherapy via hepatic artery as salvage treatment for patients with liver-only metastases from colorectal cancer , 2005 .

[13]  J. Faivre,et al.  Time trends in the treatment and survival of recurrences from colorectal cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  M. Pocard,et al.  Hepatectomy plus intraoperative radiofrequency ablation and chemotherapy to treat technically unresectable multiple colorectal liver metastases , 2005, Journal of surgical oncology.

[15]  J. Ferlay,et al.  Cancer incidence and mortality in Europe, 2004. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  F. Lévi,et al.  Tumor Progression While on Chemotherapy: A Contraindication to Liver Resection for Multiple Colorectal Metastases? , 2004, Annals of surgery.

[17]  Bernard Paule,et al.  Rescue Surgery for Unresectable Colorectal Liver Metastases Downstaged by Chemotherapy: A Model to Predict Long-term Survival , 2004, Annals of surgery.

[18]  D. Tregouet,et al.  Thymidylate Synthase Gene Polymorphism Predicts Toxicity in Colorectal Cancer Patients Receiving 5-Fluorouracil-based Chemotherapy , 2004, Clinical Cancer Research.

[19]  F. Lévi,et al.  Resection of non resectable liver metastases after chemotherapy: Prognostic factors and long term results , 2004 .

[20]  J. García-Foncillas,et al.  Triplet therapy with oxaliplatin, irinotecan, 5-fluorouracil and folinic acid within a combined modality approach in patients with liver metastases from colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  A. Abad,et al.  Biweekly irinotecan (CPT-11) plus 5-FU as first-line chemotherapy for elderly patients with metastatic colorectal cancer (MCRC). Final results of the Spanish Digestive Group (TTD) study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Ychou,et al.  Resection of previously unresectable liver metastases from colorectal cancer (LMCRC) after chemotherapy (CT) with CPT-11/L-OHP/LV5FU (Folfirinox): A prospective phase II trial , 2004 .

[23]  P. Rougier,et al.  Cetuximab+FOLFIRI as first-line treatment for metastatic colorectal CA. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  N. Ziras,et al.  Oxaliplatin (L-OHP) combined with irinotecan (CPT-11), leucovorin (LV) and fluorouracil (5-FU) compared with irinotecan, leucovorin and fluorouracil as first-line treatment for metastatic colorectal cancer (MCC): Preliminary results of a multicenter randomized phase III trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  E. Van Cutsem,et al.  Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  S. Groshen,et al.  A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer , 2004, British Journal of Cancer.

[27]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[28]  F. Giuliante,et al.  Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  Kenneth Hess,et al.  Recurrence and Outcomes Following Hepatic Resection, Radiofrequency Ablation, and Combined Resection/Ablation for Colorectal Liver Metastases , 2004, Annals of surgery.

[30]  L. Rubbia‐Brandt,et al.  Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  J. Pignon,et al.  Results of R0 Resection for Colorectal Liver Metastases Associated With Extrahepatic Disease , 2004, Annals of Surgical Oncology.

[32]  C. Tournigand,et al.  FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  N. Kemeny,et al.  An update on hepatic arterial infusion chemotherapy for colorectal cancer. , 2003, The oncologist.

[34]  L. Zelek,et al.  Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial). , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  H. Lenz,et al.  Molecular predictors of treatment and outcome in colorectal cancer , 2003, Current gastroenterology reports.

[36]  R. Adam,et al.  Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  J. Pignon,et al.  Extrahepatic disease does not contraindicate hepatectomy for colorectal liver metastases , 2003, The British journal of surgery.

[38]  D. Kerr,et al.  Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial , 2003, The Lancet.

[39]  Tom Mala,et al.  Hepatic resection for colorectal metastases: Can preoperative scoring predict patient outcome? , 2002, World Journal of Surgery.

[40]  Yoshihiro Sakamoto,et al.  Genetic and histological assessment of surgical margins in resected liver metastases from colorectal carcinoma: minimum surgical margins for successful resection. , 2002, Archives of surgery.

[41]  N. Magné,et al.  Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  M. Kemeny.  Hepatic artery infusion of chemotherapy as a treatment for hepatic metastases from colorectal cancer. , 2002, Cancer journal.

[43]  J. Figueras,et al.  Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases , 2001, The British journal of surgery.

[44]  T. Grube,et al.  [Resection of colorectal liver metastases. What prognostic factors determine patient selection?]. , 2001, Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen.

[45]  D. Nitti,et al.  Patterns of Recurrence after Resection of Colorectal Liver Metastases: Prediction by Models of Outcome Analysis , 2001, World Journal of Surgery.

[46]  F. Lévi,et al.  Five-Year Survival Following Hepatic Resection After Neoadjuvant Therapy for Nonresectable Colorectal [Liver] Metastases , 2001, Annals of Surgical Oncology.

[47]  H. Lenz,et al.  Determinants of prognosis and response to therapy in colorectal cancer , 2001, Current oncology reports.

[48]  L. Saltz,et al.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. , 2000, The New England journal of medicine.

[49]  C. Wilson,et al.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  S. Kawasaki,et al.  Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. , 2000, Annals of surgery.

[51]  S. Groshen,et al.  Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[52]  H. Bismuth,et al.  Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization. , 2000, Annals of surgery.

[53]  R. James,et al.  Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial , 2000, The Lancet.

[54]  L H Blumgart,et al.  Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. , 1999, The New England journal of medicine.

[55]  H. Pitt,et al.  Cryotherapy extends the indications for treatment of colorectal liver metastases. , 1999, Surgery.

[56]  T. Starzl,et al.  Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. , 1999, Journal of the American College of Surgeons.

[57]  F. Maley,et al.  Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  F. Lévi,et al.  Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[59]  M. Borner.  Neoadjuvant chemotherapy for unresectable liver metastases of colorectal cancer--too good to be true? , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[60]  N. Kemeny,et al.  Arterial, portal, or systemic chemotherapy for patients with hepatic metastasis of colorectal carcinoma. , 1999, Journal of hepato-biliary-pancreatic surgery.

[61]  P. Dupont,et al.  Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  Y. Fong.  Surgical therapy of hepatic colorectal metastasis , 1999, CA: a cancer journal for clinicians.

[63]  G Milano,et al.  © 1999 Cancer Research Campaign Article no. bjoc.1998.0098 Dihydropyrimidine dehydrogenase deficiency and , 2022 .

[64]  W. Bechstein,et al.  Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen) , 1998, Annals of surgery.

[65]  U. Stenram,et al.  Resection of Colorectal Liver Metastases: 25-Year Experience , 1998, World Journal of Surgery.

[66]  D. Elias,et al.  How I Do It: Intraoperative use of radiofrequency treatment allows an increase in the rate of curative liver resection , 1998, Journal of surgical oncology.

[67]  B. Nordlinger,et al.  Long‐term survival following resection of colorectal hepatic metastases , 1997, The British journal of surgery.

[68]  W. Enker,et al.  Liver resection for colorectal metastases. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  T. Baère,et al.  Preoperative portal vein embolization for extension of hepatectomy indications , 1996, Hepatology.

[70]  F. Lévi,et al.  Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. , 1996, Annals of surgery.

[71]  B. Nordlinger,et al.  Surgical resection of colorectal carcinoma metastases to the liver: A prognostic scoring system to improve case selection, based on 1568 patients , 1996, Cancer.

[72]  A. Altendorf-Hofmann,et al.  Factors influencing the natural history of colorectal liver metastases , 1994, The Lancet.

[73]  P. Rougier,et al.  Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  T. Ravikumar,et al.  Resection of hepatic metastases from colorectal cancer. Biologic perspective. , 1989, Annals of surgery.

[75]  M. Adson.  Resection of liver metastases—When is it worthwhile? , 1987, World Journal of Surgery.

[76]  R. Andersson,et al.  Major liver resection: perioperative course and management. , 1986, Surgery.

[77]  D. Ilstrup,et al.  Resection of hepatic metastases from colorectal cancer. , 1984, Archives of surgery.

[78]  S. Ricci,et al.  Biweekly irinotecan, oxaliplatin, and infusional 5-FU/LV (FOLFOXIRI) versus FOLFIRI as first-line treatment of metastatic colorectal cancer (MCRC): Results of a randomized, phase III trial by the Gruppo Oncologico Nord Ovest (G.O.N.O.) , 2006 .

[79]  D. Bentrem,et al.  CASH (Chemotherapy-Associated Steatohepatitis) costs. , 2006, Annals of surgery.

[80]  Peter Boyle,et al.  Cancer incidence and mortality in Europe , 2005, Sozial- und Präventivmedizin.

[81]  Mark Levine,et al.  Radiation therapy and tamoxifen: concurrent or sequential? That is the question. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  Richard Stang,et al.  Resection of colorectal liver metastases , 1997, Journal of Gastrointestinal Surgery.

[83]  M. Lorenz,et al.  Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  F. Lévi,et al.  Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  Peter Schlag,et al.  Resection of the liver for colorectal carcinoma metastases , 1988, Diseases of the colon and rectum.